Diseases account for the highest number of deaths that are being recorded in different parts of the world. Although there are numerous companies offer top-notch medical and health solutions when it comes to pharmaceutical drugs to combat diseases as top causes of deaths, Amicus Therapeutics, Inc. (Nasdaq: FOLD) stands out. For starters, Amicus Therapeutics is an international biotechnology company with a reputation when it comes to therapy and care of a wide range of rare and orphan diseases.
Amicus Therapeutics was founded in 2002 with its headquarters being in Cranbury, New Jersey. In 2007 the, the company went public trading its shares for the first time under the trading symbol of FOLD. Although the company does not involve itself in manufacturing pharmaceutical drugs, it makes use of different medicines and technology when providing quality health care services to its patients. Some of the rare diseases the company is known to offer solutions to include Epidermolysis Bullosa (EB), a genetic skin disorder, Pompe disease and Lysosomal Storage Disorders Fabry disease to name but a few. Learn more about job offerings of Amicus Therapeutics at indeed.com.
Key factors that have helped Amicus Therapeutics maintain its reputation in the market include its commitment and mission in the market. When forming Amicus Therapeutics, the founders had the patients at the back of their minds. Amicus Therapeutics products and services are uniquely crafted to meet the needs of the ailing patients and also their caregivers. The company can achieve this by focusing its scientific research, clinical programs and commercial organization to meet their clients’ needs.
Currently going by Amicus Therapeutics lead product, migalastat, a product that will help in the treatment of Fabry disease based on genetic diagnosis, then its true to say that the company is on the right track. Amicus Therapeutics has been led by John F. Crowley as its chief executive officer since 2005. Read the company profile at Crunchbase.